[go: up one dir, main page]

BR0013638A - New interferon beta-like molecules - Google Patents

New interferon beta-like molecules

Info

Publication number
BR0013638A
BR0013638A BR0013638-7A BR0013638A BR0013638A BR 0013638 A BR0013638 A BR 0013638A BR 0013638 A BR0013638 A BR 0013638A BR 0013638 A BR0013638 A BR 0013638A
Authority
BR
Brazil
Prior art keywords
interferon
amino acid
polypeptide
molecules
interferon beta
Prior art date
Application number
BR0013638-7A
Other languages
Portuguese (pt)
Inventor
Anders Hjelholt Pedersen
Hans Thalsgaard Schambye
Kim Vilbour Andersen
Claus Bornaes
Poul Baad Rasmussen
Original Assignee
Maxygen Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxygen Aps filed Critical Maxygen Aps
Publication of BR0013638A publication Critical patent/BR0013638A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nanotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

"NOVAS MOLéCULAS SEMELHANTES A INTERFERON BETA". Conjugado que exibe atividade de interferon <225> e que compreende pelo menos uma primeira porção não-polipeptídica ligada de modo covalente a um polipeptídeo de interferon <225>, a seq³ência de aminoácidos que difere daquela de interferon <225> humano de tipo selvagem em pelo menos um resíduo de aminoácido introduzido e pelo menos um resíduo de aminoácido removido que compreende um grupo de anexação para a referida primeira porção não-polipeptídica. A primeira porção não-polipeptídica é, por exemplo, uma molécula polimérica ou uma porção de açúcar. O conjugado encontra uso particular em terapia."NEW INTERFERON BETA SIMILAR MOLECULES". Conjugate exhibiting interferon? Activity and comprising at least a first non-polypeptide moiety covalently linked to an interferon? Polypeptide, the amino acid sequence that differs from that of wild-type human interferon? at least one introduced amino acid residue and at least one removed amino acid residue comprising an attachment group for said first non-polypeptide moiety. The first non-polypeptide moiety is, for example, a polymeric molecule or a sugar moiety. The conjugate finds particular use in therapy.

BR0013638-7A 1999-08-27 2000-08-25 New interferon beta-like molecules BR0013638A (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DKPA199901197 1999-08-27
US16078299P 1999-10-21 1999-10-21
DKPA199901691 1999-11-26
DKPA200000194 2000-02-07
DKPA200000363 2000-03-07
DKPA200000642 2000-04-14
PCT/DK2000/000471 WO2001015736A2 (en) 1999-08-27 2000-08-25 Interferon-beta conjugates

Publications (1)

Publication Number Publication Date
BR0013638A true BR0013638A (en) 2002-05-14

Family

ID=27545189

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0013638-7A BR0013638A (en) 1999-08-27 2000-08-25 New interferon beta-like molecules

Country Status (14)

Country Link
EP (1) EP1328295A2 (en)
JP (1) JP2003527090A (en)
KR (1) KR20020034181A (en)
CN (1) CN1501815A (en)
AU (1) AU6687000A (en)
BR (1) BR0013638A (en)
CA (1) CA2380760A1 (en)
CZ (1) CZ2002521A3 (en)
HU (1) HUP0302674A2 (en)
IL (1) IL147581A0 (en)
MX (1) MXPA02001969A (en)
NO (1) NO20020929L (en)
SK (1) SK2942002A3 (en)
WO (1) WO2001015736A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1042098B (en) 1998-10-16 2009-10-30 拜奥根Idec马萨诸塞公司 Interferon-beta fusion proteins and uses
TR200101086T2 (en) 1998-10-16 2001-08-21 Biogen, Inc. Polymer compounds and uses of Interferon beta-1A.
US7431921B2 (en) 1999-08-27 2008-10-07 Maxygen Aps Interferon beta-like molecules
US7144574B2 (en) 1999-08-27 2006-12-05 Maxygen Aps Interferon β variants and conjugates
AU2002212107A1 (en) * 2000-11-02 2002-05-15 Maxygen Aps New multimeric interferon beta polypeptides
BR0207576A (en) * 2001-02-27 2004-04-27 Maxygen Aps Glycosylated variant of an interferon beta precursor (ifnb) polypeptide, processes for increasing the in vivo glycosylation of a precursor ifnb molecule, producing a glycosylated ifnb molecule, preparing a conjugated variant, and treating a mammal with multiple sclerosis pharmaceutical composition , variant ifnb molecule, nucleotide sequence, expression vector, conjugated glycosylation host cell, and use of a conjugate
US20030091544A1 (en) * 2001-03-13 2003-05-15 Vical Incorporated Interferon-Beta polynucleotide therapy for autoimmune and inflammatory diseases
KR100511749B1 (en) * 2001-11-06 2005-09-02 선바이오(주) Modified interferon-beta, and chemically modified conjugates thereof
NZ534708A (en) 2002-01-18 2007-05-31 Biogen Idec Inc Polyalkylene glycol with moiety for conjugating biologically active compound
WO2004020468A2 (en) * 2002-08-28 2004-03-11 Maxygen Aps Interferon beta-like molecules for treatment of cancer
CN102319437B (en) 2002-12-26 2017-10-13 山景医药公司 Polymer conjugates of interferon-beta with enhanced biological utility
WO2005019260A1 (en) 2003-08-25 2005-03-03 Toray Industries, Inc. INTERFERON-β COMPOSITE
EP1674113A1 (en) * 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol)
RU2009107894A (en) * 2006-08-08 2010-09-20 Новартис АГ (CH) RECOMBINANT INTERFERON-BETA WITH INCREASED BIOLOGICAL ACTIVITY
US7625555B2 (en) 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
CL2008002399A1 (en) * 2007-08-16 2009-01-02 Pharmaessentia Corp Substantially pure conjugate having a polymeric portion, a protein portion (interferon alpha 2b) and an aliphatic binder of 1 to 10 carbon atoms, useful in the treatment of hepatitis b or c.
CN104043112B (en) * 2014-07-01 2016-03-30 哈药集团生物工程有限公司 A kind of ointment pharmaceutical composition containing recombinanthumaninterferonα-2b (pseudomonas)
RS65015B1 (en) 2014-11-06 2024-01-31 Pharmaessentia Corp Dosage regimen for pegylated interferon
CA3023883A1 (en) * 2016-05-13 2017-11-16 Orionis Biosciences Nv Targeted mutant interferon-beta and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4917888A (en) * 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
DE3676670D1 (en) * 1985-06-26 1991-02-07 Cetus Corp SOLUBILIZATION OF PROTEINS FOR PHARMACEUTICAL COMPOSITIONS BY POLYMER CONJUGATION.
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5218092A (en) * 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
IL113280A (en) * 1994-04-12 2004-12-15 Res Dev Foundation Composition for treating auto-immune diseases using type one interferons
US5738846A (en) * 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
EP1017794A1 (en) * 1997-02-06 2000-07-12 Novo Nordisk A/S Polypeptide-polymer conjugates having added and/or removed attachment groups
CA2296770A1 (en) * 1997-07-14 1999-01-28 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
TR200101086T2 (en) * 1998-10-16 2001-08-21 Biogen, Inc. Polymer compounds and uses of Interferon beta-1A.

Also Published As

Publication number Publication date
CA2380760A1 (en) 2001-03-08
HUP0302674A2 (en) 2003-11-28
IL147581A0 (en) 2002-08-14
CN1501815A (en) 2004-06-02
AU6687000A (en) 2001-03-26
SK2942002A3 (en) 2002-08-06
WO2001015736A2 (en) 2001-03-08
CZ2002521A3 (en) 2002-05-15
MXPA02001969A (en) 2003-07-21
KR20020034181A (en) 2002-05-08
EP1328295A2 (en) 2003-07-23
NO20020929L (en) 2002-04-25
JP2003527090A (en) 2003-09-16
NO20020929D0 (en) 2002-02-26
WO2001015736A3 (en) 2003-05-22

Similar Documents

Publication Publication Date Title
BR0013638A (en) New interferon beta-like molecules
BR0015506A (en) Gamma interferon conjugates, methods for their preparation, pharmaceutical compositions that comprise the molecules and their use in the treatment of diseases
BR0207576A (en) Glycosylated variant of an interferon beta precursor (ifnb) polypeptide, processes for increasing the in vivo glycosylation of a precursor ifnb molecule, producing a glycosylated ifnb molecule, preparing a conjugated variant, and treating a mammal with multiple sclerosis pharmaceutical composition , variant ifnb molecule, nucleotide sequence, expression vector, conjugated glycosylation host cell, and use of a conjugate
BR8906988A (en) TETRAPIPTIDIO, PEPTIDE, PHARMACEUTICAL COMPOSITION, PROCESS FOR USE OF PEPTIDE AND REAGENT FOR DIAGNOSIS
BR9808881A (en) Compounds for prostate cancer immunotherapy and methods for their use
DK0643726T3 (en) Human p53 protein peptides for use in compositions that induce human T cell response and human p53 protein
BR9907259A (en) Compounds for therapy and diagnosis of lung cancer and processes for their use
BR9907189A (en) Products of the lipid fraction of the sea cucumber carotenoid and methods of use
BR9911305A (en) Nitrate salts, process for preparing the same, pharmaceutical compositions, and use of them
ATE289350T1 (en) TNF RECEPTOR, TNF BINDING PROTEINS AND DNA CODING THEREOF
PT82834B (en) PROCESS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS, WITH PROTEIN SULBILIZATION, USING POLYMER CONJUGATION
ATE389724T1 (en) HUMAN DNASE I HYPERACTIVE VARIANTS
BR9915940A (en) Methods and compositions to restore the conformational stability of a protein of the p53 family
BR9807734A (en) Compound for prostate cancer immunodiagnosis and methods for the use of memos
BR9910573A (en) Antipicornoviral compounds, preparation and use thereof
BR9508467A (en) Somatostatin receptor binding peptide matter composition pharmaceutical composition and process for performing radiosotope-guided surgery or a radiodiagnostic or radiotherapeutic procedure and for alleviating a somatostetin-related disease in an animal
PT820303E (en) ANALYSIS OF P277 PEPTIDE AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM FOR TREATMENT OR DIAGNOSIS OF DIABETES
BR9813514A (en) Agent for the treatment of keratin fibers
BR9607628A (en) Biologically isolated proteinaceous molecule, recombinant molecule, peptide fragment, nucleic acid molecule, pharmaceutical composition, and processes for preparing a recombinant molecule and for inducing astroglial proliferation in a mammal
ZA87141B (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors,biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
FI972170A7 (en) Peptides capable of binding to the SH3 domain of a GAP protein, nucleotide sequences encoding these peptides, their preparation and use
BR0016419A (en) Method for increasing immunization responses with respect to herpes simplex virus vaccine
BR9807332A (en) Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
BR0014803A (en) Peptide, pharmaceutical composition, use of one or more of the peptides, and diagnostic composition
BR9811422A (en) Process for inhibiting vascular smooth muscle cell hyperplasia in a human patient or other warm-blooded animal patient requiring such treatment, use of at least one sulfated oligosaccharide, and pharmaceutical or veterinary composition for inhibiting muscle cell hyperplasia vascular smooth

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1962 DE 12/08/2008.

B15K Others concerning applications: alteration of classification

Free format text: PROCEDIMENTO AUTOMATICO DE RECLASSIFICACAO. A CLASSIFICACAO IPC ANTERIOR ERA A61K 47/48.

Ipc: B82Y 5/00 (2011.01), A61K 38/21 (2006.01)

Ipc: B82Y 5/00 (2011.01), A61K 38/21 (2006.01)